MedDataX Logo

Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)

NCT ID: NCT01244217

Last Updated: 2013-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

\- To evaluate safety (4 weeks)

Secondary Objectives:

* To evaluate the long-term safety (12 weeks)
* To evaluate the efficacy
* To characterize the pharmacokinetic profile

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis Perennial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Age 6 months - 2 years

Patients between 6 months and 2 years old

Group Type EXPERIMENTAL

fexofenadine/Allegra (M016455)

Intervention Type DRUG

Pharmaceutical form:dry syrup formulation to be suspended in water

Route of administration: oral

Age 2 - 11 years

Patients between 2 and 11 years (and under 10.5 kg)

Group Type EXPERIMENTAL

fexofenadine/Allegra (M016455)

Intervention Type DRUG

Pharmaceutical form:dry syrup formulation to be suspended in water

Route of administration: oral

Age 2 - 11 years (and over 10.5 kg)

Patients between 2 and 11 years (and over 10.5 kg)

Group Type EXPERIMENTAL

fexofenadine/Allegra (M016455)

Intervention Type DRUG

Pharmaceutical form:dry syrup formulation to be suspended in water

Route of administration: oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fexofenadine/Allegra (M016455)

Pharmaceutical form:dry syrup formulation to be suspended in water

Route of administration: oral

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 6 months through 11 years
* Patients with perennial allergic rhinitis

Exclusion Criteria

* Neither serum specific IgE antibody or skin reaction is positive for the antigen of perennial allergy.
* Nasal symptom score is 0 for either sneezing or nasal discharge, or sum of these two score is less than 3, or nasal congestion score is 4.
* Patients with vasomotor rhinitis or eosinophilic rhinitis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Minimum Eligible Age

6 Months

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sanofi-Aventis Investigational Site Number 392015

Fukuoka, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392012

Kanazawa, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392001

Kawaguchi-Shi, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392003

Kawasaki-Shi, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392004

Kawasaki-Shi, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392002

Kita-ku, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392011

Kofu, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392014

Obu-Shi, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392013

Seki-Shi, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392005

Yokohama, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392006

Yokohama, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392007

Yokohama, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392008

Yokohama, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392009

Yokohama, , Japan

Site Status

Sanofi-Aventis Investigational Site Number 392010

Yokohama, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1115-3842

Identifier Type: OTHER

Identifier Source: secondary_id

SFY10717

Identifier Type: -

Identifier Source: org_study_id